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Brief Report
ABSTRACT
In the prospective phase 3 HOVON-50/GMMG-HD3 trial, patients randomized to TAD (thalidomide, doxorubicin, dexamethasone) had
a significantly higher response rate (at least PR) after induction compared with patients randomized to VAD (vincristine, adriamycin,
dexamethasone, 72% vs. 54%, p<0.001). Complete remission (CR) and very good partial remission (VGPR) were also higher after TAD.
After High Dose melphalan 200mg/m2 response was comparable in both arms, 76% and 79% respectively. However, CR plus VGPR
were significantly higher in the patients randomized to TAD (49% vs. 32%, p<0.001). CTC grade 3-4 adverse events were similar in
both arms.
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Introduction
Induction therapy, such as the combination of vincristine,
doxorubicin and dexamethasone (VAD), followed by stem
cell collection and autologous stem cell transplantation is cur-
rently considered the standard treatment for younger myelo-
ma patients.1,2,3 Recently thalidomide-based regimens have
been shown to be highly effective as first line treatment in
terms of response and event free survival. New induction
schedules like the thalidomide-dexamethasone combination
are advocated as preparation regimens, with the rationale that
these increase the initial response rate which may result in a
higher (complete) response rate and prolonged survival fol-
lowing high-dose therapy and autologous stem cell transplan-
tation.4-8 However, others have questioned the value of VAD
as initial therapy in multiple myeloma (MM) and have
emphasized the care needed before drawing conclusions from
surrogate outcomes such as response rate.9 The objective of
the HOVON 50 MM/GMMG-HD3 phase 3 trial was to eval-
uate the efficacy of thalidomide combined with intensive
therapy in previously untreated patients.10
Design and Methods
Patients with newly diagnosed MM, Salmon and Durie
stage II or III, age 18-65 years, were eligible for inclusion in
the HOVON-50/GMMG-HD3 study. Informed consent was
obtained prior to randomization. According to the
Declaration of Helsinki, the protocol was approved by the
Research Ethics Board of each participating hospital. Patients
were randomly assigned to arm A: 3 cycles of VAD: vin-
cristine (0.4 mg, IV rapid infusion on days 1-4), doxorubicin (9
mg/m2, IV rapid infusion on days 1-4) and dexamethasone 40
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mg orally (days 1-4, 9-12, 17-20)11 or to arm B, the same
regimen but with thalidomide 200 - 400 mg orally, days
1-28 instead of vincristine (TAD). Cycle 2 started at day
29, cycle 3 at day 57. Thalidomide was started at day 1
of the first TAD cycle and was stopped 2 weeks before
stem cell mobilization was started. The thalidomide
dose could be escalated to a maximum 400 mg when
tolerability was good. Patients in arm B received throm-
bosis prophylaxis consisting of subcutaneously low
molecular weight heparin (LMWH) nadroparine 2,850
IE anti-Xa or 5,700 anti-Xa when weight >90 kg.12 Stem
cells were mobilized using the CAD regimen, i.e.
cyclophosphamide 1000 mg/m2 iv day 1, doxorubicin
15 mg/m2, iv rapid infusion on days 1-4, dexamethasone
40 mg orally on days 1-4, given at 4-6 weeks after induc-
tion treatment, plus G-CSF 5 mg/kg twice daily until
collection. After induction therapy, all patients were to
receive 1 or 2 courses of high dose Melphalan (HDM)
200 mg/m2 with autologous stem cell rescue. Centers
committed to single or double HDM before start of
study. Patients randomized to arm A received mainte-
nance therapy with a-interferon (3×106 IU, three times
week) and patients randomized to arm B received
Thalidomide 50 mg daily without venous thromboem-
bolism (VTE) prophylaxis. Response was evaluated as
intention to treat according to the EBMT criteria and
required a negative immune fixation for patients in
CR.14 Recently, achievement of a VGPR, defined as a
90% or greater reduction in the serum M-protein plus
urinary M-protein level < 100 mg/24 hours has been rec-
ognized. This criterion was, therefore, also included in
the response evaluation.15 Response was evaluated after
induction treatment and at least 3 months after HDM 1.
Results and Discussion
A first interim analysis was performed on 402 patients
of the 1,240 included in the trial, 201 patients per treat-
ment arm with validated data, registered before August
2004. Median age was 56 years (range 34-65), 248 male
and 154 female patients. Most patients (81%) had stage
III myeloma according to Salmon and Durie. According
to the International Staging System (ISS) 163 patients
were in stage I, 81 in stage II and 78 in stage III, while
80 patients could not be classified due to missing b2-
microglobulin and/or albumin data.13 Patient character-
istics were in general equally distributed between both
arms (Table 1).
The total response (≥ PR) after 3 courses of TAD was
significantly higher compared with the response after 3
courses of VAD (72% vs. 54%, p<0.001). In addition,
VGPR plus CR was higher in patients receiving TAD
(arm B, 33% CR 4%) vs. VAD (arm A, 15%; CR 2%,
p<0.001). Total response rates (PR, VGPR plus CR) fol-
lowing HDM1 were comparable in both arms: VAD
+HDM1; 76%, TAD plus HDM1; 79% (p=0.55).
However, TAD followed by HDM1 resulted in a signif-
icantly higher proportion of patients achieving VGPR
plus CR, 49% vs. 32% (p<0.001), while the CR percent-
ages were not statistically different (16% vs. 11%,
p=0.19). The ISS had no impact on response rate, nor
was there an association between ISS and treatment
arm. Thalidomide could be given at full dose to 62% of
patients, was reduced in 17% of patients, had to be
stopped in 19% of patients, while no data were avail-
able for 2% of patients. CTC grade 3-4 events were
recorded in 33% of patients during VAD and in 41% of
patients during TAD (p=0.13). Grade 3-4 neurology
occurred in 7% of patients during VAD and in 12% of
patients during TAD (p=0.09). All grade 3-4 adverse
events during induction therapy are listed in Table 2.
Twenty seven patients (13%) in arm A and 37 patients
(18%) in arm B went off protocol treatment without
receiving HDM, mainly due to excessive toxicity (3%),
intercurrent death (6%) or progressive disease (5%)
comparable in both arms. The incidence of VTE during
induction therapy was published previously.12 In short:
Table 1. Patient characteristics. 
Arm A: VAD Arm B: TAD Total
Total 201 201 402
Sex
male 115 133 248
female 86 68 154
Age
median 56 57 56
range 36-65 34-65 34-65
M-protein
IgA 47 38 85
IgG 108 127 235
IgM 1 1 2
IgD 1 3 4
LCD 42 30 72
unknown 2 2 4
Serum b-2M
Median mg/L 3.1 3.6 3.3
range 0.1  - 34.8 0.5 – 53.6 0.1  - 53.6
number 172 172 344
Albumin g/L 
median 36.0 3542 36
range 20-53.0 4.2-57.4 4.2-57.4
number 182 181 363
Stage S and D
IIA 37 33 70
IIB 1 1 2
IIIA 134 139 273
IIIB 28 26 54
unknown 1 2 3
ISS
I 87 75 162
II 37 43 80
III 33 45 78
unknown 44 38 82
S and D: Salmon and Durie; LCD: light chain disease; ISS: International Staging
System.
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VTE incidence in both arms was reported to be compa-
rable (Arm A, 4% and Arm B, 8%, p=0.08). 
Impressive response rates have been reported for first
line therapies that combine the conventional anti-
myeloma drugs with novel agents such as thalidomide,
lenalidomide or bortezomib.16-18 Our study shows that
more effective induction therapy by including thalido-
mide not only improves the remission status after
induction but that the superior response is maintained
until after intensification. It is remarkable that this bet-
ter response was only reflected by a higher percentage
of VGPR while total response and CR rate were not
improved. Do these results further support the value of
VAD as initial therapy in multiple myeloma? One
would think so, although the better quality of the
response induced by thalidomide must be balanced
against the greater toxicity and the need for VTE pro-
phylaxis associated with the combination. It is not yet
known whether these increased response rates are
translated in prolonged EFS and OS. Recently published
studies showed that only thalidomide maintenance fol-
lowing autologous transplantation prolonged event-free
survival (EFS) and overall survival (OS) while thalido-
mide given during all phases of treatment (induction,
intensification and maintenance), only prolonged EFS
but not OS, due to multi-drug resistant relapses after
transplantation.19,20
We conclude that thalidomide as part of initial treat-
ment improves pre- and post-transplant response by
increasing the percentages of patients achieving a VGPR.
Longer follow-up is needed to establish the effect on
long term outcome. Our study supports the exploration
of other combinations with novel agents that may
induce even higher response rates and are probably asso-
ciated with fewer side effects. Promising schemes in this
respect are bortezomib, dexamethasone, with or with-
out doxorubicin (PAD) and lenalidomide combined with
dexamethasone.16-18
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Table 2. Number (%) of patients with adverse events CTC grade 3-
4 during VAD/TAD cycles 1-3. 
Arm A: VAD (n=199 )* Arm B: TAD (n=200)* p value
N % N %
Any adverse event 66 33 81 41 0.13
Allergy/immunology − − 1 1 1.00
Auditory/hearing − − 1 1 1.00
Cardiovascular arrythmi 3 2 3 2 1.00
Cardiovascular. function 15 8 17 9 0.72
Coagulation 4 2 7 4 0 .54
Constitutional symptoms 10 5 14 7 0.41
Dermatology/skin 3 2 2 1 0 .69
Endocrine 3 2 4 2 1.00
GI 10 5 16 8 0.23
Hemorrhage 1 1 3 2 0.62
Hepatic 7 4 6 3 0 .77
Lymphatic 1 1 − − 0.50
Metabolic 17 9 10 5 0.16
Musculoskeletal 2 1 2 1 1.00
Neurology 14 7 24 12 0 .09
Ocular − − 1 1 1.00
Pain 9 5 9 5 0.99
Pulmonary 7 4 7 4 0.99
GU and renal 1 1 3 2 0 .62
Other 1 1 1 1 1.00
* Adverse events data were not available in 3 patients (2 in arm A, 1 in arm B).
There were some (expected) events, that didn’t have to be reported as adverse
events (diarrhea, mucositis). 
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